STOCKHOLM, June 14, 2018 /PRNewswire/ --
More than 11,000 participants from around the world are expected at the upcoming 23rd Congress of the European Hematology Association (EHA) at the Stockholmsmässan, Stockholm, Sweden on June 14-17, 2018, where the latest data on hematology research and development will be presented as well as two new programs EHA is launching on Immunotherapy and Hemoglobinopathies
(Logo: http://mma.prnewswire.com/media/622259/EHA_Logo.jpg )
In two Press Briefings, a selection of these will be presented to the media.
Friday, June 15, 2018 from 08:30-10:00 hours CEST in Room K11
Moderator: Elizabeth Macintyre
Abstract Presenter Title
S138 Jesus G. Berdeja Update on bb2121, a promising therapy for patients
with heavily pre-treated relapsed/refractory
multiple myeloma
S110 Olivier Casasnovas AHL2011: Outstanding disease control with a
minimized BEACOPP exposure and toxicity in
patients with advanced Hodgkin lymphoma
S149 Fang Liu First-in-Human CLL1-CD33 Compound CAR T Cells as a
Two-pronged Approach for the treatment of
refractory acute myeloid leukemia
S151 Valentin Goede Overall survival benefit of obinutuzumab over
rituximab when combined with chlorambucil in
patients with chronic lymphocytic leukemia and
comorbidities
S154 Frank Morschhauser Is RELEVANCE Relevant? Results of the phase III
study of R2 vs R-chemo in first-line follicular
lymphoma
S152 Francesca Vinchi Iron: a double-edged sword in inflammation
Saturday, June 16, 2018 from 08:30-09:30 hours CEST in Room K11
Moderator: Ton Hagenbeek
Abstract Presenter Title
S832 Jing Pan New anti-CD22 CAR-T immunotherapy saved life
of children with leukemia
S852 Meletios iNNOVATE Study: Ibrutinib plus Rituximab for
Dimopoulos Patients with Waldenström's Macroglobulinemia
S802 Laurie H. Sehn Answering the unmet need in one of the most
common types of lymphoma: It's as simple as A-D-C
In addition to these abstracts, a new EHA program called Topics-in-Focus will be presented on Saturday, June 16:
- 09:05 - 09:10: Immunotherapy -> Making CAR-T cells happen in Europe by John Gribben, Barts Cancer Institute, London, United Kingdom.
- 09:15-09:20: Hemoglobinopathies -> From the basics of sickle cell disease to where we are now by Maria Cappellini, University of Milan-Foundation IRCCS Policlinico Hospital, Italy.
Embargo
Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information check our Congress Media Guidelines here. Are you interested in the program of the 23rd Congress? This can be found here.
Website: http://www.ehaweb.org
